Altimmune Stock
€7.75
Your prediction
Altimmune Stock
Pros and Cons of Altimmune in the next few years
Pros
Cons
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Altimmune, Inc. (ALT) seem to present a mixed picture. The company has managed to maintain a relatively stable asset base over the past few years, but a consistent net loss in its income statements indicates ongoing challenges in operational efficiency. In order to provide a more comprehensive evaluation, this article will delve into the pros and cons of the company's financial performance.
Stable Total Assets: A closer look at the balance sheets reveals that Altimmune's total assets have remained relatively consistent throughout the years, with USD 206.9 million in 2022, USD 218.9 million in 2021, and USD 245.1 million in 2020. This stability suggests that the company is maintaining its asset base and could indicate financial stability.
High Net Working Capital: ALT's net working capital is quite strong, showing a surplus of resources to meet short-term obligations. In 2022, their net working capital was USD 175.8 million, indicating a healthy liquidity position.
Comments
News
Can Altimmune's weight-loss drug be a game-changer?
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold rush for new weight-loss drugs in the medical